Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
ivermectin (Soolantra®)
Reference No. 1627
Publication date:
01/04/2016
Appraisal information
ivermectin (Soolantra®) 10 mg/g cream
Company:
Galderma (UK) Ltd
BNF category:
Skin
NMG meeting date:
20/01/2016
AWMSG meeting date:
24/02/2016
Submission Type:
Full Submission
Status:
Recommended
Advice No:
0216
Ratification by Welsh Government:
24/03/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Ivermectin (Soolantra®) is recommended as an option for use within NHS Wales for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.
Final Appraisal Recommendation (FAR)
Download
ivermectin (Soolantra) 1627 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
ivermectin (Soolantra) 1627 ASAR
Clinical Expert (CE) Summary
Download
ivermectin (Soolantra) 1627 CE summary